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Impact of cilostazol after endovascular treatment
for infrainguinal disease in patients with critical
limb ischemia
Yoshimitsu Soga, MD,a Osamu Iida, MD,b Keisuke Hirano, MD,c Kenji Suzuki, MD,d
Daizo Kawasaki, MD,e Yusuke Miyashita, MD,f Taketsugu Tsuchiya, MD,g and
Masakiyo Nobuyoshi, MD,a Kitakyushu, Amagasaki, Yokohama, Sendai, Nishinomiya, Nagano,
and Kanazawa, Japan
Background: Cilostazol reduces restenosis and repeat revascularization after endovascular therapy (EVT) in claudicant
patients with femoropopliteal lesions. However, the efficacy of cilostazol in patients with critical limb ischemia (CLI) is
unclear. Therefore, we investigated the effect of cilostazol on outcomes in patients with CLI.
Methods: From January 2004 to December 2009, 618 patients (30.8% women, 356 treated with cilostazol, 72.4  7.3
years old) with CLI underwent EVT for de novo infrainguinal lesions. Their data were retrospectively analyzed. The
primary outcome measure was amputation-free survival (AFS), The secondary outcome measures were overall survival,
limb salvage, freedom from repeat revascularization, and freedom from surgical conversion. Mean follow-up was 21 14
months.
Results: AFS and the limb salvage rate at 5 years were significantly higher in the cilostazol-treated group (47.7% vs 32.7%,
P < .01; 86.6% vs 75.3%, P < .01; respectively). However, overall survival and freedom from repeat revascularization at
5 years did not differ significantly between the two groups (43.9% vs 46.0%, P  .24; 39.9% vs 31.8%, P  .21,
respectively). Freedom from surgical conversion at 5 years was significantly higher in the cilostazol-treated group (91.0%
vs 81.2%, P < .01). After correcting all end points with baseline variables, cilostazol was effective for prevention of AFS
(hazard ratio [HR], 0.67; 95% confidential interval [CI], 0.49-0.91; adjusted P .01) and improvement of limb salvage
rate (HR, 0.42; 95% CI, 0.25-0.69; adjusted P < .01). There was no significant difference in overall survival, repeat
revascularization, and surgical conversion between the groups.
Conclusions: Cilostazol may improve AFS and limb salvage rate after EVT for infrainguinal disease in patients with CLI.
(J Vasc Surg 2011;54:1659-67.)
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cThe primary goals of treatment of patients with critical
limb ischemia (CLI) are pain control and ischemic release
by revascularization.1,2 However, age, comorbidities, and
general conditions often make it difficult to perform surgi-
cal revascularization. Many recent studies have shown the
efficacy of endovascular therapy (EVT) in patients with
CLI,3-7 and several studies have reported that EVT has
outcomes similar to those of surgery.8-10 This suggests that
more patients with CLI are likely to undergo EVT, but
appropriate medical therapy after EVT has not been inves-
tigated.
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doi:10.1016/j.jvs.2011.06.024Cilostazol has an inhibitory effect on restenosis after
ercutaneous coronary intervention,11 and several studies
n patients with peripheral artery disease (PAD) have shown
mprovement of walking distance in intermittent claudica-
ion,12 restenosis after femoropopliteal stenting,13 and a
educed need for revascularization in claudicant patients.14
owever, the efficacy of cilostazol has not been examined
n patients with CLI.
The basic treatment methods for CLI patients are pain
ontrol and revascularization. At present, therapy that im-
roves the outcome of CLI has not been established, and
here has been limited discussion of the efficacy of adjuvant
herapy after revascularization in CLI patients. In addition,
everal drugs are being used empirically for treatment of
his condition without clear evidence of the reasons for
heir use. Therefore, we evaluated the efficacy of cilostazol
fter EVT in patients with CLI due to infrainguinal lesions.
ETHODS
The study protocol was approved by the Ethics Com-
ittees of the participating hospitals, and the study was
erformed in accordance with the Declaration of Helsinki.
ritten informed consent was obtained from every patient.
Study design. The study was performed as a multi-
enter, prospectivemaintained database, retrospective anal-
sis. Between January 2004 and December 2009, consec-
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December 20111660 Soga et alutive 828 patients with CLI underwent EVT at seven
cardiovascular centers in Japan. The analysis excluded 122
patients with an aortoiliac lesion and 88 patients with
congestive heart failure. Therefore, 618 patients (618 first
treated limbs) who underwent EVT with CLI for de novo
infrainguinal lesions were identified retrospectively and in-
cluded in the analysis. Baseline demographic and clinical
characteristics data were collected from each hospital data-
base.
Procedures and follow-up. All patients were medi-
Table I. Patients’ characteristics
Variablea
Cilostazol therapy
P
Yes No
(n  356) (n  262)
Age, years 72.0  11.3 71.3  9.5 .44
Male (%) 242 (68.0) 165 (63.0) .20
BMI, kg/m2 21.4  3.4 21.9  2.9 .09
Hypertension 291 (81.7) 213 (81.3) .89
Dyslipidemia 252 (70.8) 189 (72.1) .71
Diabetes (%) 258 (72.5) 205 (78.2) .10
Hemodialysis 170 (47.8) 151 (57.6) .02
Current smoker 107 (30.1) 61 (23.3) .06
COPD 22 (6.2) 13 (5.0) .52
CVD 131 (36.8) 92 (35.1) .67
CAD 179 (50.3) 150 (57.3) .09
LV dysfunctionb 31 (8.7) 18 (6.9) .40
Rutherford class .65
4 96 62
5 197 151
6 63 49
CLI in other leg 58 (16.3) 43 (16.4) .97
Poor runoff 258 (72.3) 183 (69.8) .48
Ambulatory 160 (44.9) 115 (43.9) .80
ABI
Preprocedure 0.67  0.30 0.69  0.31 .57
Postprocedure 0.84  0.27 0.84  0.25 .88
SPP, mm Hg
Preprocedure 30.6  19.2 29.1  19.1 .35
Postprocedure 49.8  19.9 44.2  22.0 .002
CRP, mg/dL 2.3  3.6 2.7  4.7 .25
Procedure success 332 (93.3) 236 (90.1) .15
Lesion location
FP 122 (34.3) 92 (35.1) .44
BTK 221 (62.1) 165 (63.0)
FP  BTK 13 (3.7) 5 (1.9)
Medication
Aspirin 310 (87.8) 216 (82.4) .06
Thienopyridine 96 (27.2) 134 (51.3) .0001
ACEI/ARB 106 (29.8) 94 (35.9) .11
Calcium antagonist 218 (61.2) 153 (58.4) .48
-Blockade 23 (6.5) 14 (5.3) .56
Statins 78 (22.1) 56 (21.5) .85
Warfarin 63 (17.8) 47 (18.0) .95
ABI, Ankle-brachial index; ACEI, angiotensin converting enzyme inhibi-
tors; ARB, angiotensin receptor blockers; BTK, below-the-knee; CLI, crit-
ical limb ischemia; COPD, chronic obstructive pulmonary disease; CRP,
C-reactive protein;CVD, cardiovascular death; FP, femoropopliteal; LV, left
ventricular; SPP, skin perfusion pressure.
aContinuous data are presented as mean  standard deviation; categoric
data as number (%).
bLV dysfunction was defined as a left ventricular ejection fraction 40%.cated with dual antiplatelet therapy consisting of aspirin w100 mg/day) and clopidogrel (75 mg/day) before the
rocedure. After insertion of a 4F or 6F sheath from a
rossover approach or an antegrade ipsilateral approach, an
ntra-arterial bolus of 3000 to 5000 IU of heparin was
njected, with additional heparin given intravenously dur-
ng the procedure to maintain the activated clotting time at
200 seconds.
For femoropopliteal lesion, balloon angioplasty was
erformed with an optimal size after a 0.035-, 0.018-, or
.014-inch guidewire crossed the lesion. If a suboptimal
esult caused by flow-limiting dissection or residual stenosis
f 30% was found for the femoropopliteal lesion, a stent
as implanted. The entire lesion was covered by the stent.
wo types of nitinol stents were implanted: Luminexx
Bard, Murray Hill, NJ) and SMART (Cordis, Johnson &
ohnson, Miami, Fla). The stent type was determined by
he operators, and the stent size chosen was 1 to 2 mm
arger than the reference vessel diameter.
For infrapopliteal lesions, the target lesion was passed
ith a 0.018- or 0.014-inch guidewire, the diameter and
ength of the balloon were determined by the operator, and
he vessel was expanded for at least 120 seconds. When
ow-limiting dissection, significant recoil, or acute occlu-
ion was found after balloon angioplasty, balloon angio-
lasty was repeatedly performed with low pressure and a
ong inflation time. Bailout stenting for infrapopliteal lesion
able II. Lesion characteristics
ariablea
Cilostazol therapy
P
Yes No
(n  356) (n  262)
emoropopliteal lesion
Lesion length, mm 161  83 155  93 .61
Ref vessel diameter, mm 5.1  0.7 5.1  0.8 .75
Stenosis
Prediameter, % 89.8  15.8 88.5  16.1 .52
Postdiameter, % 32.7  16.2 33.5  14.4 .68
Chronic total occlusion 84 (63.2) 51 (52.6) .11
TASC II classification
A 26 27 .27
B 28 14
C 37 30
D 44 26
Stent fracture 8 (6.1) 10 (10.3) .24
elow-the-knee lesion
Lesion length, mm 173  93 170  89 .84
Ref vessel diameter, mm 2.4  0.4 2.4  0.4 .32
Stenosis, %
Prediameter 99.2  3.7 99.0  3.9 .75
Postdiameter 52.5  27.3 53.7  30.3 .68
Chronic total occlusion 222 (94.9) 158 (92.9) .42
TASC II classification .46
A 2 3
B 5 5
C 5 4
D 222 158
ASC, TransAtlantic Inter-Society Consensus.
Continuous data are presented as mean  standard deviation; categoric
ata as number (%).as not performed.
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Volume 54, Number 6 Soga et al 1661After the procedure, all patients were prescribed life-
long aspirin (100-200 mg/day), and prolonged (1
month) clopidogrel (75 mg/day) was recommended for
patients who received femoropopliteal stenting. For pa-
tients who received balloon angioplasty, aspirin alone was
recommended. At the discretion of the surgeon, thien-
opyridine or cilostazol (200 mg/day) was added. Aspirin
and thienopyridine or cilostazol were started by the day
before EVT or earlier. Additional dosage was determined
by the doctor in charge of each patient.
Cilostazol administration was continued after hospital
discharge for an average of 20  17 months, but was
discontinued in some patients because of side effects. Pa-
tients who were receiving cilostazol at hospital discharge
were included in the cilostazol group. Patients who had
already taken cilostazol before the procedure continued to
receive cilostazol after the procedure.
All patients were assessed at 1, 3, and 6months after the
procedure, and then every 6 months thereafter. Wound
care was conducted together with revascularization in all
cases by consulting a vascular surgeon or a plastic surgeon
in each center. Repeat revascularization was performed on
the basis of ischemic-driven symptoms or clinical findings.
Outcome measures. The primary outcome measure
was amputation-free survival (AFS). Secondary outcome
measures were overall survival, limb salvage rate, freedom
from repeat revascularization, and freedom from surgical
Fig 1. Kaplan-Meier curves show amputation-free sur
cilostazol therapy.conversion. fDefinitions. CLI was defined as Rutherford category
, 5, or 6. Procedure success was defined as straight-line
ow to the pedal arch with 30% of residual stenosis after
VT. Limb salvage was defined as freedom from the am-
utation above the ankle. Coronary artery disease (CAD)
as defined as stable angina with documented CAD, his-
ory of percutaneous coronary intervention or coronary
rtery bypass grafting, or previous myocardial infarction.
erebrovascular disease was defined as a hospital or neurol-
gist report with the diagnosis of transient ischemic attack
r ischemic stroke. A heart failure case was determined to
e a patient with a previous diagnosis of heart failure, a
istory of hospitalization for heart failure, or current treat-
ent for heart failure.
Diabetes was defined as glycosylated hemoglobin A1C
HbA1C) of 6.5%, casual plasma glucose of 200 mg/
L, or patients who were treated with oral hypoglycemic
gents or insulin injection. Hypertension was defined as
ystolic blood pressure 140 mm Hg or diastolic blood
ressure 90 mm Hg, or both, or ongoing therapy for
ypertension.
Below-the-knee (BTK) runoff was assessed by angiog-
aphy before or after procedure. Poor runoff was defined as
ne or no BTK vessel runoff. Left ventricular ejection
raction was measured by contrast left ventriculography or
chocardiography. Patients with left ventricular ejection
rate in patients who did () and did not (–) receivevivalraction 40% were regarded as having left ventricular
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December 20111662 Soga et aldysfunction. Elderly patients were defined as patients aged
75 years.
Statistical analysis. Continuous variables are ex-
pressed as mean  standard deviation, unless otherwise
indicated, and were compared using the t test or Wilcoxon
rank sum test based on the distribution. Categoric variables
were compared by 2 test. Survival curves were estimated
by the Kaplan-Meier method and compared with the log-
rank test.
The consistency of the treatment effect was assessed
among seven prespecified subgroups comprising gender,
elderly, ambulatory, infrapopliteal lesion, diabetes, hemo-
dialysis, or tissue loss. The effect in each subgroup was
analyzed with the use of a Cox proportional hazard model,
without adjustment for covariates. Hazard ratio (HR), 95%
confidence intervals (CI), and P value were calculated with
the use of models adjusted for the baseline characteristics
with P .10 on univariate analysis. A value of P .05 was
considered statistically significant.
RESULTS
Baseline characteristics. The baseline characteristics
of the patients are listed in Table I. The average age was
72.4  7.3 years, and 30.8% were women. Ischemic rest
pain was present in 25.6% and tissue loss in 74.4%. The
Fig 2. Kaplan-Meier curves show limb salvage rate in
therapy.mean follow-up period was 21.0  13.8 months. Use of thienopyridine was less frequent and body mass index and
he incidence of coronary disease were lower in the cilostazol-
reated group. All other baseline characteristics were similar
n the two groups.
Femoropopliteal lesions alone were treated in 192
atients (31.1%), infrapopliteal lesions alone in 386
62.5%), and both lesions in 20 (3.2%). Bilateral CLI was
bserved in 101 patients (16.3%). Postprocedure skin
erfusion pressure (SPP) was significantly higher in the
ilostazol-treated group (49.8  19.9 vs 44.2  22.0
m Hg, P .002). Lesion characteristics were similar in
oth groups (Table II).
Procedure success. EVT was performed in 618 legs
nd was successful in 568 (91.9%). Of the 50 legs with poor
utcomes, 18 were treated with lower extremity bypass and
2 with drug therapy. Subsequently, major amputation was
equired in 3 patients who underwent lower extremity
ypass and in 22 of those who received drug therapy.
Primary and secondary outcome measures. The
FS rate was significantly higher in the cilostazol () group
t 5 years than in the cilostazol (–) group (47.7% vs 32.7%;
og-rank P  .001; Fig 1). The limb salvage rate was also
ignificantly higher in the cilostazol group at 5 years (86.6%
s 75.3%; log-rank P .004; Fig 2). However, there was no
ignificant difference in overall survival rate between the
ients who did () and did not (–) receive cilostazolpatwo groups at 5 years (43.9% vs 46.0%; log-rank P  .24;
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Volume 54, Number 6 Soga et al 1663Fig 3). Freedom from cardiovascular death at 5 years
tended to be higher in the cilostazol () group (70.4% vs
65.7%; log-rank P  .08; Fig 4). No significant difference
of freedom from repeat revascularization was found in
either group at 5 years (39.9% vs 31.8%; log-rank P  .21;
Fig 5). However, freedom from surgical conversion was
significantly higher in the cilostazol group at 5 years (91.0%
vs 81.2%; log-rank P  .001).
After correcting all end points with the prespecified
baseline variables of sex, age, body mass index, diabetes,
smoker, CAD, hemodialysis, and use of thienopyridine,
cilostazol was effective for prevention of AFS (HR, 0.67;
95% CI, 0.49-0.91; adjusted P  .011) and limb salvage
rate (HR, 0.42; 95% CI, 0.25-0.69; adjusted P  .001).
There was no significant difference in overall survival (HR,
1.04; 95% CI, 0.73-1.47; adjusted P .84) and cardiovas-
cular death (HR, 1.04; 95% CI, 0.63-1.71; adjusted P 
.89) between the groups. The observed reduction in con-
version of bypass surgery after EVT observed in the cilosta-
zol group did not attain statistical significance (HR, 0.46;
95% CI, 0.21-1.01; adjusted P  .052; Table III).
Univariate prespecified subgroup analysis for the AFS
was performed (Fig 6). Cilostazol was effective for men,
nonelderly patients (aged 75 years), patients with an
infrapopliteal lesion, diabetic patients, nondialysis patients,
Fig 3. Kaplan-Meier curves show overall survival rate
therapy.and patients with tissue loss, especially, Rutherford class 5. wilostazol also tended to be effective for women and am-
ulatory patients (Fig 6).
ISCUSSION
The results of this study showed that cilostazol im-
roved AFS in patients with CLI due to lesions in the leg
elow the groin. The limb salvage rate was significantly
igher in the cilostazol group, but the all-cause mortality
as similar; therefore, the improved limb salvage rate ap-
eared to contribute greatly to the improved AFS. How-
ver, although cilostazol did not affect repeat revasculariza-
ion, limb salvage was improved. A postoperative increase
n peripheral perfusion pressure may have contributed to
he improved limb salvage rate, because the postoperative
PPmeasured at 1 week to 1month after the procedure was
ignificantly higher in the cilostazol group (49.8 vs 44.2
m Hg; P  .002; Table I). Miyashita et al15 found that
ilostazol increased SPP in PAD patients and suggested
hat cilostazol administration may increase microcircula-
ion in a severely ischemic limb. Verification of this finding
equires a prospective study of restenosis rate and changes
n SPP based on periodic follow-up angiograms.
The results of subgroup analysis indicated that cilosta-
ol was effective in patients with a severe background,
ncluding infrapopliteal lesions, diabetes and tissue loss, but
tients who did () and did not (–) receive cilostazolin paas less effective in cases with a poor prognosis, including
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December 20111664 Soga et alelderly patients and dialysis patients (group with a short
observation period).
In the subanalysis of 386 legs with one infrapopliteal
lesion, cilostazol significantly improved AFS (HR, 0.70;
95% CI, 0.51-0.96; unadjusted P  .03) and limb salvage
(HR, 0.51; 95% CI, 0.30-0.85; unadjusted P  .01) but
did not influence overall survival (HR, 0.85; 95% CI,
0.60-1.22; unadjusted P  .38). All patients in this study
with infrapopliteal lesions were treated with balloon angio-
plasty. Cilostazol is more effective for prevention of reste-
nosis after revascularization in CAD patients treated with
balloon angioplasty than in those treated with stenting.12
This is because intimal proliferation is more active after
balloon angioplasty than after stenting, especially drug-
eluting stent implantation.
The effect on lower extremity vessels is unknown, but
we also found that cilostazol-treated patients with an infra-
popliteal lesion that was treated with balloon angioplasty
had a decreased tendency for repeat revascularization (HR,
0.73; 95% CI, 0.50-1.05; unadjusted P  .08), suggesting
an effect of cilostazol. Stenting (especially drug-eluting
stent implantation) for infrapopliteal lesions is more effec-
tive than balloon angioplasty for prevention of resteno-
sis.16-19 However, although the primary patency at 1 year
after balloon angioplasty is low (58.1%  4.6%), the limb
salvage rate was high (86.0%  2.7%).7 Similarly, Schmidt
Fig 4. Kaplan-Meier curves show freedom from cardiov
receive cilostazol therapy.et al20 indicated that the rate of restenosis observed in dngiography 3 months after balloon angioplasty was ex-
remely high (68.8%) and that half of the patients required
eintervention; however, the limb salvage rate after 15
onths was 100%, and no patient required surgical revas-
ularization. These results indicate that the restenosis rate
oes not always correlate positively with major amputation,
nd therefore, the use of a stent is currently limited to
ailout procedures.
In the current study, the efficacy of cilostazol was
nclear in 158 patients without tissue loss, but with rest
ain. At 2 years after treatment, the AFS in patients with
est pain was significantly higher than that in patients with
issue loss (80.3% vs 51.1%; P  .0001, log-rank test) and
he rate of major amputation was significantly lower (5.0%
s 21.7%; P  .0001, log-rank test). Only six patients, two
ilostazol () and four cilostazol (–), required major am-
utation during the observation period (P  .16). The
vent incidence was not high in patients with rest pain;
herefore, further larger-scale studies of the efficacy of
ilostazol are required in these patients.
Diabetic patients with CLI have extremely high mor-
idity of 71% to 90%.5,20 Of the 618 patients in the current
tudy, 463 (74.9%) were diabetic. The overall survival at 2
ears was 68.6% in the diabetes group vs 64.5% in the
ondiabetes group (P  .37, log-rank test); however,
he limb salvage rate at 2 years was significantly lower in the
ar death (CVD) in patients who did () and did not (–)asculiabetes group (80.7% vs 89.5%; P  .02, log-rank test).
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Volume 54, Number 6 Soga et al 1665Overall survival in the 173 diabetes patients with good
glucose control (HbA1C 7%) was similar to that in the
290 patients with poor glucose control (HbA1C 7%), at
63.1% vs 72.5% at 2 years (P .38, log-rank test). The limb
salvage rate at 2 years was significantly lower in patients
with poor glucose control (71.9% vs 85.9%; P  .0004,
log-rank test).
Previous findings showed that the presence of diabetes
and the HbA1C level have no relationship with death in
patients with CLI who underwent EVT, but are prognostic
Fig 5. Kaplan-Meier curves show freedom from repea
receive cilostazol therapy.
Table III. Primary and secondary outcome measures
Outcome measures
Cilostazol therapy no. (%)
Yes No
(n  356) (n  262)
Primary
Amputation-free survival 126 (35.4) 110 (42.0)
Secondary
Limb salvage 38 (10.7) 46 (17.6)
Overall survival 114 (32.0) 85 (32.4)
Cardiovascular death 47 (13.2) 43 (16.4)
Repeat revascularization 112 (31.5) 83 (31.7)
Surgical conversion 16 (4.5) 24 (9.2)
CI, Confidence interval; HR, hazard ratio.
aAdjusted results were adjusted for prespecified risk factors: age, sex, body m
of thienopyridine.factors for major amputation,21 and the results of this study supported these findings. In diabetic patients, cilostazol
mproved AFS (HR, 0.68; 95% CI, 0.50-0.90; unadjusted
 .008) and the limb salvage rate (HR, 0.49; 95% CI,
.30-0.78; unadjusted P  .003), but was ineffective for
ll-cause mortality (HR, 0.84; 95% CI, 0.60-1.16; P 
28). A greater inhibitory effect of cilostazol on restenosis
as shown in diabetes patients with coronary disease who
nderwent percutaneous coronary intervention,22 and the
esults of the current study also suggested that cilostazol
ay be more effective in patients with diabetes. Further
scularization in patients who did () and did not (–)
HR (95% CI)
Unadjusted P
HR (95% CI)
Adjusteda P
.70 (0.54-0.90) .006 0.67 (0.49-0.91) .011
.54 (0.35-0.83) .005 0.42 (0.25-0.69) .0008
.85 (0.64-1.12) .25 1.04 (0.73-1.47) .84
.69 (0.45-1.04) .08 1.04 (0.63-1.71) .89
.83 (0.63-1.11) .21 0.85 (0.61-1.18) .32
.45 (0.24-0.84) .013 0.46 (0.21-1.01) .053
ex, diabetes, current smoker, coronary artery disease, hemodialysis, and uset reva0
0
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0tudies are required to confirm the efficacy, but patients
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December 20111666 Soga et alwith CLI are very likely to have diabetes, and improvement
of these cases by pharmacotherapy is important.
Cilostazol had no effect on end points in dialysis pa-
tients. At 2 years, the mortality rate was 40.2% in dialysis
patients vs 23.9% in nondialysis patients (P  .0001, log-
rank test), and the rate of major amputation was also
significantly higher (21.8% vs 12.1% P  .002; log-rank
test). The outcomes of dialysis patients complicated with
CLI are extremely poor, and intervention with pharmaco-
therapy has limited ability to improve these outcomes.
Therefore, an individual treatment strategy should be es-
tablished for high-risk patients, including diabetic and di-
alysis patients, in addition to further accumulation of these
cases.
Pharmacotherapy is often ineffective in patients with
CLI.23 In TransAtlantic Inter-Society Consensus II,2 the
basic treatment proposed for patients with CLI was revas-
cularization and pain control. However, it remains unclear
whether pharmacotherapy is a potential option for patients
who are ineligible for revascularization or in whom revas-
cularization has failed. Antiplatelet therapy is also prefera-
ble for patients with PAD after revascularization because it
reduces the risks of systemic vascular events in all types of
PAD; however, it is unclear whether antiplatelet therapy
has a similar efficacy for patients with CLI, who have poor
outcomes of the lower extremities and poor survival. This
situation emphasizes the importance of the results of this
study confirming the efficacy of cilostazol for AFS and limb
Fig 6. Univariate subgroup analysis shows amputation-f
with those who did not receive cilostazol.salvage in patients with CLI after EVT. aThis study has several limitations: First, this was a
etrospective, nonrandomized analysis, despite being a
arge-scale, multicenter study; therefore, a prospective ran-
omized investigation is needed to verify these findings.
Second, patients with infrapopliteal lesions were
reated with balloon angioplasty and accounted for approx-
mately two-thirds of the patients in the study. Further
tudies should be conducted to analyze whether bailout
nd primary stenting have similar effects.
Finally, because of potential adverse reactions to
ilostazol, patients complicated with heart failure were
xcluded from the study. However, heart failure has been
ound to be a prognostic factor for patients with CLI,24 and
urther studies should also be conducted in patients with
LI complicated with heart failure.
ONCLUSIONS
In this retrospective study, CLI patients in whom
ilostazol could be or was given before EVT for infraingui-
al lesions and could be continued after the procedure
xperienced a better amputation-free survival and limb
alvage rate than those in whom cilostazol could not or was
ot given.
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